Repligen (RGEN) Tops Q2 EPS by 5c, misses on revenue, provides guidance
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $166.83 --0%
Financial Fact:
Selling, general and administrative: 7.13M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Selling, general and administrative: 7.13M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.53, $0.05 better than the analyst estimate of $0.48. Revenue for the quarter came in at $159.2 million versus the consensus estimate of $165.93 million.
GUIDANCE:
Repligen sees FY2023 revenue of $635-665 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
- Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
